Please ensure Javascript is enabled for purposes of website accessibility

This Bidding War Was a Bidding Skirmish

By Dave Williamson - Apr 9, 2013 at 3:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The bidding war for Obagi Medical Products is over, and everyone's a winner.

Though many excited traders had hoped to see the bidding war continue between Valeant Pharmaceuticals (BHC -2.17%) and Merz over Obagi Medical Products (NASDAQ: OMPI) and a subsequent run-up in the stock price of the smaller dermatological products maker, Merz has now walked away from the table, leaving the highly acquisitive Valeant the victor. In this video, Motley Fool health care analyst David Williamson gives us some background on these companies and tells us how Valeant plans to profit from the deal, and describes for investors why this is a win both for Obagi and for Valeant.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$9.93 (-2.17%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.